Fundz

Vaxcyte, Inc. has priced concurrent public offerings, raising approximately $500 million from common stock and $500 million from convertible senior notes to fund clinical development.

PUBLIC · PCVXOct 07, 2026

Amount Raised

$1 Billion

Round Type

Convertible Note

San CarlosBiotechnologyHealth CareTherapeutics

Description

Vaxcyte, Inc. announced the pricing of concurrent underwritten public offerings, including common stock, pre-funded warrants, and convertible senior notes. The company expects to raise approximately $500 million from the offerings. Funds will support clinical development of its vaccine programs

Quick answer

Vaxcyte, Inc. raised $1 Billion in a Convertible Note round, dated October 7, 2026. Vaxcyte, Inc. is based in San Carlos, California, United States.

How much did Vaxcyte, Inc. raise?
Vaxcyte, Inc. raised $1 Billion in a Convertible Note round on October 7, 2026.
Where is Vaxcyte, Inc. based and how big is it?
Vaxcyte, Inc. is based in San Carlos, California, United States. Fundz records about 510 employees.
Who are the decision-makers at Vaxcyte, Inc?
Fundz holds 4 contacts at Vaxcyte, Inc., including the Senior Manager, Talent Acquisition & Talent Operations. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as Vaxcyte, Inc. that raised within 45 days of this round, from Fundz verified event records.

  • Lifeplex Science raised $5.3M (Series A) on November 13, 2026.
  • Orakl Oncology raised $34M (Series A) on November 12, 2026.
  • VectorY raised $83M on November 11, 2026.
  • Neurosterix raised $105M (Series B) on November 11, 2026.
  • Oyster Therapeutics raised $60M (Series A) on November 10, 2026.
  • SRTD biotech raised $35M (Seed) on November 9, 2026.

Who to call at Vaxcyte, Inc., and when

A new round usually means Vaxcyte, Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Vaxcyte, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Vaxcyte, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Vaxcyte, Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Vaxcyte, Inc.

Location

825 Industrial Road, Ste. 300

San Carlos, California, United States

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Vaxcyte, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

4 contacts
Verified contactsJon N., Senior Manager, Talent Acquisition & Ta… hidden hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Vaxcyte, Inc.'s next move

See what Strategic adds

Vaxcyte, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.